Updates are available Correction dated 2024-07-10
Click to view Correction: https://doi.org/10.1186/s13195-024-01507-7
-
Authors
Honig, Lawrence S.
Sabbagh, Marwan N.
van Dyck, Christopher H.
Sperling, Reisa A.
Hersch, Steven
Matta, Andre
Giorgi, Luigi
Gee, Michelle
Kanekiyo, Michio
Li, David
Purcell, Derk
Dhadda, Shobha
Irizarry, Michael
Kramer, Lynn
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 31 March 2024
First Online: 10 May 2024
Change Date: 10 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-024-01507-7
Declarations
:
: The trial was approved by the institutional review board or independent ethics committee at each center and all participants provided informed consent.
: Not applicable.
: LSH receives research funding from Abbvie, Acumen, Alector, Biogen, Bristol-Myers Squibb, Cognition, EIP, Eisai, Ferrer, Genentech/Roche, Janssen/J&J, Transposon, UCB, Vaccinex. LSH is a consultant for Alector, Biogen, Cortexyme, Eisai, Medscape, and Prevail/Lilly.MNS has ownership interest (Stock or stock options): NeuroTau, uMethod Health, Versanum, Athira, TransDermix, Seq BioMarque, NeuroReserve, Cortexyme/Quince Therapeutics, Lighthouse Therapeutics. MNS is a consultant for: Alzheon, Biogen, Roche-Genentech, Eisai, KeifeRx, Lilly, Synaptogenix, NeuroTherapia, T3D, Signant Health, Novo Nordisk. MNS receives royalties from Humanix. MNS is a Board of Director for EIP Pharma.CHvD is a consultant for Roche, Eisai, Cerevel, and Ono and receives research support from Biogen, Eisai, Roche, Genentech, Eli Lilly, Janssen, UCB, Cerevel, and Biohaven.RAS is a consultant to: AbbVie, AC Immune, Acumen, Alector, Bristol-Myers Squibb, Genentech, Ionis, Janssen, Oligomerix, Prothena, Roche, Shionogi. RAS receives research funding from the National Institute on Aging (P01AG036694; R01AG054029; R01AG061848, U24AG057437; R01 AG03689), the Alzheimer’s Association, GHR Foundation, Eli Lilly, Eisai – Public-Private Partnership Trial Funding, and. Accelerating Medicines Partnership FNIH.SH, AM, LG, MG, MK, DL, SD, MI, and LK are employees of Eisai.DP is an employee of Clario.
